// App-Quantinova.ai

Su1939 : SUSTAINED REMISSION WITH VEDOLIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A GEMINI 1 POST HOC ANALYSIS OF WEEK 14 REMITTERS

Researchers

Presenter

  • Andreas Stallmach

Principal Investigators

  • Jeffrey L. Axler

  • Brian G. Feagan

  • Rebecca I. Curtis

  • Robert Ehehalt

  • Stefan Schreiber

  • Parnia Geransar

  • Alexandra James

  • Arpeat Kaviya

  • Javaria M. Khalid

  • Douglas C. Wolf

Medical Centers

  • Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

  • Gastroenterology, Hepatology and Infectiology, Friedrich-Schiller-Universitat Jena, Jena, Germany

  • Gastroenterology Practice, Minden, Germany

  • Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Germany

  • Gastroenterology, Praxis fur Gastroenterologie, Heidelberg, Germany

  • Emory Saint Joseph's, Atlanta Gastroenterology Associates, Atlanta, Georgia, United States

  • Toronto Digestive Disease Associates Inc.

Locations

  • United States

  • Canada

  • Germany

Companies

  • Takeda Pharmaceutica

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • Unknown

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved